FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease

Thumbnail
2022
Acidosis_cognitive_dysfunctio_pub_2022.pdf (2.677Mb)
Authors
Imenez Silva, Pedro H.
Unwin, Robert
Hoorn, Ewout J.
Ortiz, Alberto
Trepiccione, Francesco
Nielsen, Rikke
Pešić, Vesna
Hafez, Gaye
Fouque, , Denis
Massy, Ziad A.
De Zeeuw, Chris I.
Capasso, Giovambattist
Wagner, Carsten
Article (Published version)
Metadata
Show full item record
Abstract
Metabolic acidosis, defined as a plasma or serum bicarbonate concentration <22 mmol/L, is a frequent consequence of chronic kidney disease (CKD) and occurs in ~10-30% of patients with advanced stages of CKD. Likewise, in patients with a kidney transplant, prevalence rates of metabolic acidosis range from 20% to 50%. CKD has recently been associated with cognitive dysfunction, including mild cognitive impairment with memory and attention deficits, reduced executive functions and morphological damage detectable with imaging. Also, impaired motor functions and loss of muscle strength are often found in patients with advanced CKD, which in part may be attributed to altered central nervous system (CNS) functions. While the exact mechanisms of how CKD may cause cognitive dysfunction and reduced motor functions are still debated, recent data point towards the possibility that acidosis is one modifiable contributor to cognitive dysfunction. This review summarizes recent evidence for an associa...tion between acidosis and cognitive dysfunction in patients with CKD and discusses potential mechanisms by which acidosis may impact CNS functions. The review also identifies important open questions to be answered to improve prevention and therapy of cognitive dysfunction in the setting of metabolic acidosis in patients with CKD.

Keywords:
acidosis / chronic kidney disease / cognitive dysfunction / klotho / motor function
Source:
Nephrology Dialysis Transplantation, 2022, 37, supplement 2, ii4-ii12
Publisher:
  • Oxford University Press
Funding / projects:
  • COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
  • Swiss National Science Foundation–financed NCCR Kidney.
  • FIS/Fondos FEDER [PI18/01366, PI19/00588, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009)], Sociedad Española de Nefrología, FRIAT and Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM.

DOI: 10.1093/ndt/gfab216

ISSN: 0931-0509

WoS: 000740945100002

Scopus: 2-s2.0-85123025417
[ Google Scholar ]
3
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/4028
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Imenez Silva, Pedro H.
AU  - Unwin, Robert
AU  - Hoorn, Ewout J.
AU  - Ortiz, Alberto
AU  - Trepiccione, Francesco
AU  - Nielsen, Rikke
AU  - Pešić, Vesna
AU  - Hafez, Gaye
AU  - Fouque, , Denis
AU  - Massy, Ziad A.
AU  - De Zeeuw, Chris I.
AU  - Capasso, Giovambattist
AU  - Wagner, Carsten
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4028
AB  - Metabolic acidosis, defined as a plasma or serum bicarbonate concentration <22 mmol/L, is a frequent consequence of chronic kidney disease (CKD) and occurs in ~10-30% of patients with advanced stages of CKD. Likewise, in patients with a kidney transplant, prevalence rates of metabolic acidosis range from 20% to 50%. CKD has recently been associated with cognitive dysfunction, including mild cognitive impairment with memory and attention deficits, reduced executive functions and morphological damage detectable with imaging. Also, impaired motor functions and loss of muscle strength are often found in patients with advanced CKD, which in part may be attributed to altered central nervous system (CNS) functions. While the exact mechanisms of how CKD may cause cognitive dysfunction and reduced motor functions are still debated, recent data point towards the possibility that acidosis is one modifiable contributor to cognitive dysfunction. This review summarizes recent evidence for an association between acidosis and cognitive dysfunction in patients with CKD and discusses potential mechanisms by which acidosis may impact CNS functions. The review also identifies important open questions to be answered to improve prevention and therapy of cognitive dysfunction in the setting of metabolic acidosis in patients with CKD.
PB  - Oxford University Press
T2  - Nephrology Dialysis Transplantation
T1  - Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease
VL  - 37
IS  - supplement 2
SP  - ii4
EP  - ii12
DO  - 10.1093/ndt/gfab216
ER  - 
@article{
author = "Imenez Silva, Pedro H. and Unwin, Robert and Hoorn, Ewout J. and Ortiz, Alberto and Trepiccione, Francesco and Nielsen, Rikke and Pešić, Vesna and Hafez, Gaye and Fouque, , Denis and Massy, Ziad A. and De Zeeuw, Chris I. and Capasso, Giovambattist and Wagner, Carsten",
year = "2022",
abstract = "Metabolic acidosis, defined as a plasma or serum bicarbonate concentration <22 mmol/L, is a frequent consequence of chronic kidney disease (CKD) and occurs in ~10-30% of patients with advanced stages of CKD. Likewise, in patients with a kidney transplant, prevalence rates of metabolic acidosis range from 20% to 50%. CKD has recently been associated with cognitive dysfunction, including mild cognitive impairment with memory and attention deficits, reduced executive functions and morphological damage detectable with imaging. Also, impaired motor functions and loss of muscle strength are often found in patients with advanced CKD, which in part may be attributed to altered central nervous system (CNS) functions. While the exact mechanisms of how CKD may cause cognitive dysfunction and reduced motor functions are still debated, recent data point towards the possibility that acidosis is one modifiable contributor to cognitive dysfunction. This review summarizes recent evidence for an association between acidosis and cognitive dysfunction in patients with CKD and discusses potential mechanisms by which acidosis may impact CNS functions. The review also identifies important open questions to be answered to improve prevention and therapy of cognitive dysfunction in the setting of metabolic acidosis in patients with CKD.",
publisher = "Oxford University Press",
journal = "Nephrology Dialysis Transplantation",
title = "Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease",
volume = "37",
number = "supplement 2",
pages = "ii4-ii12",
doi = "10.1093/ndt/gfab216"
}
Imenez Silva, P. H., Unwin, R., Hoorn, E. J., Ortiz, A., Trepiccione, F., Nielsen, R., Pešić, V., Hafez, G., Fouque, ,. D., Massy, Z. A., De Zeeuw, C. I., Capasso, G.,& Wagner, C.. (2022). Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. in Nephrology Dialysis Transplantation
Oxford University Press., 37(supplement 2), ii4-ii12.
https://doi.org/10.1093/ndt/gfab216
Imenez Silva PH, Unwin R, Hoorn EJ, Ortiz A, Trepiccione F, Nielsen R, Pešić V, Hafez G, Fouque ,D, Massy ZA, De Zeeuw CI, Capasso G, Wagner C. Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease. in Nephrology Dialysis Transplantation. 2022;37(supplement 2):ii4-ii12.
doi:10.1093/ndt/gfab216 .
Imenez Silva, Pedro H., Unwin, Robert, Hoorn, Ewout J., Ortiz, Alberto, Trepiccione, Francesco, Nielsen, Rikke, Pešić, Vesna, Hafez, Gaye, Fouque, , Denis, Massy, Ziad A., De Zeeuw, Chris I., Capasso, Giovambattist, Wagner, Carsten, "Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease" in Nephrology Dialysis Transplantation, 37, no. supplement 2 (2022):ii4-ii12,
https://doi.org/10.1093/ndt/gfab216 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB